For the millions of Americans living with chronic obstructive pulmonary disease (COPD), unpredictability is a constant companion. Flare-ups can strike without warning, making it difficult to plan even simple daily activities. But a new treatment option is offering hope for those whose symptoms remain inadequately controlled despite standard inhaler therapy.
COPD is a chronic, progressive lung disease that makes breathing increasingly difficult over time. Symptoms include ongoing coughing, increased mucus, wheezing, chest tightness, and shortness of breath. As the disease progresses, patients often find themselves withdrawing from activities they once enjoyed, from hobbies to social events to work.
Mark H., 60, knows this reality all too well. Diagnosed with COPD in 2010, he watched his condition worsen to the point where he had to step back from favorite hobbies and retire early from his job. “I remember feeling like, well, I guess this is my life now,” he recalls.
But according to a press release from Sanofi and Regeneron, patients like Mark may have another option. Dupixent® (dupilumab) is a prescription medicine used with other medicines for the maintenance treatment of adults with inadequately controlled COPD and a high number of blood eosinophils—a type of white blood cell that may contribute to COPD. It is not used to relieve sudden breathing problems and does not replace an inhaled rescue medicine.
Nurse practitioner Corinne Young, a pulmonology specialist who also competes in team roping events, sees parallels between COPD and rodeo. “People living with inadequately controlled COPD can experience an unpredictable life,” she says. “They don’t always know when difficulty with breathing might impact their daily activities.” Young encourages her patients to talk openly about all symptoms and how often COPD affects their daily life. “Starting that conversation can help patients and their healthcare providers determine whether an add-on treatment may be appropriate,” she adds.
In her practice, Young says some patients who added Dupixent to their COPD inhalers have experienced reduced flare-ups, better breathing in as little as two weeks, and improvement in their daily quality of life. Mark, who added Dupixent, noticed a difference: “My breathing feels deeper, I don’t feel as winded, and I’m doing more things I love.”
The news matters because COPD affects millions worldwide and remains a leading cause of disability and death. For patients who continue to struggle despite standard care, the availability of a biologic like Dupixent represents a significant shift in treatment paradigms. It underscores the importance of personalized medicine and the need for patients to have ongoing conversations with their healthcare providers about persistent symptoms.
As with any medication, Dupixent carries important safety information. Patients should not use it if allergic to dupilumab or any of its ingredients. Serious side effects can include allergic reactions, eye problems, and joint aches and pain. The most common side effects in COPD patients include injection site reactions, common cold symptoms, high eosinophil count, viral infection, back pain, rhinitis, diarrhea, gastritis, joint pain, toothache, headache, and urinary tract infection. Patients are encouraged to report negative side effects of prescription drugs to the FDA by visiting www.fda.gov/medwatch.
For full prescribing details, including indications and usage, please see the Prescribing Information and Patient Information. Patients should talk to their healthcare provider to see if adding Dupixent may be right for them.

